ArticleArthritis & rheumatology (Hoboken, N.J.)2026
Relation of Colchicine to Total Joint Arthroplasty Among People With Gout in a Population-Based Cohort Study.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo evaluate the relation of colchicine use to the risk of total joint arthroplasty (TJA) in individuals with gout, the most common form of arthritis for which colchicine is prescribed.
methodsThis new-user design, time-stratified, population-based cohort study used a UK primary care database (2000-2021). We identified participants with gout who were newly prescribed colchicine after their gout diagnosis. Each colchicine initiator was propensity score matched with a noninitiator using one-year cohort accrual blocks. The effect of colchicine on the risk of TJA was assessed using Cox proportional hazard regression. Analyses were repeated and limited to participants with both gout and knee/hip osteoarthritis (OA).
resultsWe identified 31,478 colchicine initiators who were propensity score matched to an equal number of noninitiators (mean age 60 years, mean body mass index 30), with a median follow-up time of 4.5 years. Colchicine initiators had a 12% lower risk of TJA than noninitiators (hazard ratio [HR] 0.88, 95% confidence interval [CI] 0.81-0.96), which remained similar after additional adjustment for confounders (HR 0.89, 95% CI 0.82-0.97). Colchicine initiators with gout had a 23% lower risk of TJA among those with knee/hip OA (HR 0.77, 95% CI 0.64-0.92) compared with noninitiators (HR 0.77, 95% CI 0.64-0.92).
conclusionIn this large population-based cohort of people with gout, colchicine initiation was associated with a modestly lower risk of TJA. Colchicine may offer a long-term benefit in reducing the risk of joint arthroplasty in individuals with gout and knee or hip OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.